Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Acute myelogenous leukemia (AML) is a rapidly progressing blood and bone marrow cancer characterized by the uncontrolled growth of abnormal myeloid cells that impair normal blood cell production. As per Anusha Vakiti et al. (2024), AML has an annual incidence of approximately 4.3 cases per 100,000 individuals, accounting for more than 20,000 new cases each year in the United States. According to the acute myelogenous leukemia (AML) pipeline analysis by Expert Market Research, the therapeutic landscape is advancing with the development of FLT3 Inhibitors, targeted treatments for IDH1/IDH2 Mutations, and Venetoclax AML-based combination therapies. The growing emphasis on precision oncology, novel targeted agents, immunotherapies, and improved relapse management strategies is expected to support significant pipeline expansion and market growth in the coming years.
-
Major companies involved in the acute myelogenous leukemia (AML) pipeline analysis include Sichuan Baili Pharmaceutical Co., Ltd., Bio-Path Holdings, Inc., Akeso, and others.
-
Leading drugs currently in the pipeline include BL-M11D1 + Cytarabine + Daunorubicin, BP1001 + Ventoclax + Decitabine, AK117 + Azacitidine + Venetoclax, and others.
-
Advancements in targeted AML therapies, including enasidenib treatment, expanding clinical trials, and improved integration of bone marrow transplant AML strategies are accelerating drug development, enhancing treatment outcomes, and strengthening the oncology pipeline landscape.
Report Coverage
The Acute Myelogenous Leukemia (AML) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute myelogenous leukemia (AML) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute myelogenous leukemia (AML). The acute myelogenous leukemia (AML) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute myelogenous leukemia (AML) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute myelogenous leukemia (AML) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute myelogenous leukemia (AML).
Read more about this report - Request a Free Sample
Acute Myelogenous Leukemia (AML) Pipeline Outlook
Acute myelogenous leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursor cells in the bone marrow and blood. It occurs when genetic mutations disrupt normal blood cell development, leading to the accumulation of immature leukemic blasts that impair the production of healthy red blood cells, white blood cells, and platelets.
Acute myelogenous leukemia (AML) treatment typically involves induction and consolidation chemotherapy, targeted therapies for specific genetic mutations, stem cell transplantation, and emerging immunotherapies. Treatment selection depends on disease subtype, genetic profile, patient age, and overall health status to improve remission and survival outcomes. In May 2026, the U.S. Food and Drug Administration approved the oral combination of decitabine, cedazuridine, and venetoclax for newly diagnosed acute myelogenous leukemia patients aged 75 years or older or those ineligible for intensive chemotherapy. This advancement complements evolving AML pipeline strategies, including CD33 Targeted Therapy, Gemtuzumab Ozogamicin, Midostaurin Therapy, CPX-351 Liposomal, and CAR-T Cell AML approaches, supporting expanded treatment options and improved patient management.
Acute Myelogenous Leukemia (AML) Epidemiology
The pipeline reflects growing efforts to address the increasing disease burden and unmet treatment needs. According to Anusha Vakiti et al., 2024, AML has an annual incidence of approximately 4.3 cases per 100,000 population, accounting for more than 20,000 new cases annually in the United States, with a median diagnosis age of 68 years and higher occurrence among males. As per Michelle Munroe et al., 2025, in the United Kingdom, 42% of new AML cases are diagnosed in individuals aged over 75 years, underscoring the strong association between aging populations and disease incidence. The growing AML incidence, increasing demand for targeted therapies, and advancements in precision medicine and immunotherapy are driving progress across the AML drug pipeline.
Acute Myelogenous Leukemia (AML) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of acute myelogenous leukemia (AML) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The acute myelogenous leukemia (AML) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Acute Myelogenous Leukemia (AML) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 46%, covers a major share of the total acute myelogenous leukemia (AML) clinical trials, reflecting strong mid-stage clinical development activity. Phase I accounts for 41%, highlighting a robust flow of innovative candidates entering evaluation, while phase III represents 10%, supporting potential near-term commercialization. The remaining 3% is distributed across early phase I and phase IV, strengthening overall market advancement and future growth prospects.
Acute Myelogenous Leukemia (AML) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the acute myelogenous leukemia (AML) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The acute myelogenous leukemia (AML) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute myelogenous leukemia (AML). Immune-based therapies are emerging as promising treatment options for patients with relapsed or refractory disease. For instance, CER-1236, an investigational engineered T-cell therapy, is currently under clinical evaluation. Moreover, targeted therapies and antibody-based agents are also being developed to selectively eliminate leukemic cells, improve treatment response, and reduce disease progression while enhancing patient outcomes.
Acute Myelogenous Leukemia (AML) Clinical Trials – Key Players
The EMR report for the acute myelogenous leukemia (AML) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acute myelogenous leukemia (AML) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acute myelogenous leukemia (AML) clinical trials:
- Sichuan Baili Pharmaceutical Co., Ltd.
- Bio-Path Holdings, Inc.
- Akeso
- Ascentage Pharma Group Inc.
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Aptevo Therapeutics
- Syndax Pharmaceuticals
- Moleculin Biotech, Inc.
- Kura Oncology, Inc.
- AbbVie
- CERo Therapeutics Holdings, Inc.
Acute Myelogenous Leukemia (AML) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute myelogenous leukemia (AML). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute myelogenous leukemia (AML) drug candidates.
Drug: BL-M11D1 + Cytarabine + Daunorubicin
BL-M11D1 is being evaluated in a Phase II/III clinical trial sponsored by Sichuan Baili Pharmaceutical Co., Ltd. for the treatment of acute myeloid leukemia (AML). The study examines safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 administered in combination with cytarabine plus daunorubicin or venetoclax plus azacitidine in newly diagnosed AML patients. BL-M11D1 is an investigational injectable antibody-drug conjugate (ADC) that targets CD33, a protein highly expressed on AML cells. Upon binding to CD33, the drug is internalized and releases a topoisomerase I inhibitor payload, promoting tumor cell destruction through targeted cytotoxic activity and antibody-dependent cellular cytotoxicity. The study is expected to be completed in December 2027.
Drug: BP1001 + Ventoclax + Decitabine
BP1001 is a liposomal Grb2 antisense oligonucleotide being sponsored by Bio-Path Holdings, Inc. for the treatment of acute myelogenous leukemia (AML). The Phase IIa, open-label, multicenter study is evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of BP1001 in combination with venetoclax and decitabine in patients who are ineligible for intensive induction therapy. Administered intravenously, BP1001 is designed to inhibit the production of Growth Factor Receptor-Bound Protein 2 (Grb2), a key protein involved in leukemia cell growth and survival. The study is examining whether this targeted combination therapy is achieving higher remission rates than existing treatment approaches. The estimated primary completion date is December 2027, with overall study completion expected in December 2028.
Drug: AK117 + Azacitidine + Venetoclax
AK117 is being evaluated in a Phase 1b/2 study sponsored by Akeso for patients with acute myeloid leukemia (AML). The study is examining the safety, tolerability, and efficacy of AK117 in combination with azacitidine and venetoclax. AK117 (ligufalimab) is a next-generation humanized IgG4 anti-CD47 monoclonal antibody administered intravenously that blocks the CD47–SIRPα signaling pathway, enhancing phagocyte-mediated destruction of leukemia cells and inhibiting tumor growth. The trial is enrolling AML patients with ECOG performance status 0–3, while assessing the therapeutic potential of this triplet regimen. The estimated primary completion date is April 2026, with overall study completion expected in April 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Acute Myelogenous Leukemia (AML) Pipeline Insight Report
- Which companies/institutions are leading the acute myelogenous leukemia (AML) drug development?
- Which company is leading the acute myelogenous leukemia (AML) pipeline development activities?
- What is the current acute myelogenous leukemia (AML) commercial assessment?
- What are the opportunities and challenges present in the acute myelogenous leukemia (AML) pipeline landscape?
- What is the efficacy and safety profile of acute myelogenous leukemia (AML) pipeline drugs?
- Which company is conducting major trials for acute myelogenous leukemia (AML) drugs?
- Which companies/institutions are involved in acute myelogenous leukemia (AML) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in acute myelogenous leukemia (AML)?
Reasons To Buy This Report
The acute myelogenous leukemia (AML) pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for acute myelogenous leukemia (AML). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute myelogenous leukemia (AML) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
